-
Paxlovid
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Nirmatrelvir 2628280-40-8 Ritonavir 155213-67-5 [Indication]
Paxlovid is a co-packaged combination of nirmatrelvir, a second generation protease inhibitor, and ritonavir, a pharmacological enhancer for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older with body weight ≥40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
-
Pomalidomide
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Pomalidomide 19171-19-8 ✓ Commercial Production [Indication]
Pomalidomide is indicated in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor and have progressed on or within 60 days of completion of the last therapy.
-
Pitavastatin Calcium
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Pitavastatin Calcium 147526-32-7 Commercial Production [Indication]
1. Indicated as adjunctive therapy to diet for the treatment of patients with hypercholesterolemia (including heterozygous familial hypercholesterolemia) or mixed hyperlipidemia.
2. To reduce the risk of myocardial infarction, stroke, revascularization, and hospitalization for congestive heart failure.
-
Pregabalin
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Pregabalin 148553-50-8 22223 Commercial Production [Indication]
1. For the treatment of postherpetic neuralgia.
2. For the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
3. Adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
4. For the treatment of fibromyalgia.